Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome.
about
Nanostructures for the Inhibition of Viral InfectionsFGI-104: a broad-spectrum small molecule inhibitor of viral infectionSmall-molecule inhibition of HIV pre-mRNA splicing as a novel antiretroviral therapy to overcome drug resistanceTranscriptome sequencing of gene expression in the brain of the HIV-1 transgenic rat.Synthesis of a Vpr-Binding Derivative for Use as a Novel HIV-1 InhibitorExpression of the mu opioid receptor in the human immunodeficiency virus type 1 transgenic rat modelRNA deep sequencing analysis reveals that nicotine restores impaired gene expression by viral proteins in the brains of HIV-1 transgenic ratsMechanisms and inhibition of HIV integrationMelanoma: a model for testing new agents in combination therapies.Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco.Novel macromolecular inhibitors of human immunodeficiency virus-1 protease.Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection.Ionic derivatives of betulinic acid as novel HIV-1 protease inhibitors.Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.HIV entry inhibitors and their potential in HIV therapyBevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.Evolutionary principles and their practical application.Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudineSynthesis and HIV-1 integrase inhibitory activity of spiroundecane(ene) derivativesThe therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.Anti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors.Expanding research on the role of alcohol consumption and related risks in the prevention and treatment of HIV/AIDS.Identification of HIV inhibitors guided by free energy perturbation calculations.Chronic sildenafil in men with diabetes and erectile dysfunction.Computational Studies of a Mechanism for Binding and Drug Resistance in the Wild Type and Four Mutations of HIV-1 Protease with a GRL-0519 Inhibitor.FK506-binding protein (FKBP) partitions a modified HIV protease inhibitor into blood cells and prolongs its lifetime in vivoRecruitment and ethical considerations in HIV cure trials requiring treatment interruptionAnti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agentsAlternative splicing: regulation of HIV-1 multiplication as a target for therapeutic action.Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010).Behavioral and molecular evidence for a feedback interaction between morphine and HIV-1 viral proteins.Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design.Nanotechnology: a magic bullet for HIV AIDS treatment.Synthesis of prodrug-type anti-HIV agents conjugating a REVERSE transcriptase inhibitor to a HIV-1 integrase inhibitor by a spontaneously cleavable linker.Hyperbranched molecular structures with potential antiviral activity: derivatives of 5,6-dihydroxyindole-2-carboxylic Acid.Nitroimidazoles Part 6. Synthesis, structure and in vitro anti-HIV activity of new 5-substituted piperazinyl-4-nitroimidazole derivatives.The role of nanotechnology in the treatment of viral infections.Lipid Changes in Virologically Suppressed HIV-Infected Patients Switching from any Antiretroviral Therapy to the Emtricitabine/Rilpivirine/Tenofovir Single Tablet: GeSida Study 8114.Fluorometric assay for phenotypic differentiation of drug-resistant HIV mutants.Design and characterization of an HIV-specific ribonuclease zymogen.
P2860
Q26801513-C30CA756-0102-42E9-9C4B-FF8D10E89B5BQ27490384-95432A79-805F-4042-AA7E-0D0D0157CD5CQ28469343-3DA7F5D4-A7F0-45F0-9684-11F77DD9D487Q28488809-5BE51AAE-E084-4120-88B1-FCA2A42F4172Q28551700-8CEC6506-8CC9-4E02-8713-CAB514C281D1Q28569735-DCD0E09B-3B4B-4FE7-A859-AFFCB11E8DDEQ30418181-179A86AA-B614-4C90-88D4-C636630D2ADAQ33814406-27C3E9AD-6675-4A0A-B541-28C271DFF4A8Q33863916-BA43427C-E8BA-4D00-B9DE-09E62394E863Q33957908-DD648BAA-6486-4FBD-82C0-7CE5D4173C60Q33988828-BA9C7974-5056-4619-A5BB-AAC0D9196769Q34021729-1CB2FE82-C42C-4D0D-8155-5529F687D838Q34045239-38578AAC-5D82-471A-988E-F5DDA2805AE8Q34462935-C6115184-8429-470F-B355-B20E0226563CQ34595921-571D5A0C-3A37-4210-882C-EE64CF5E0848Q34885660-D403B8C2-6FA0-4F87-9473-3D34BDD112F0Q35539621-A813EFE1-6CB0-4C36-9BC7-A92AE7A791B4Q35840864-756AA75A-59C8-45DC-BE78-22EE861F1E51Q35855680-782FB5A9-B5E4-4AB9-BF5D-D1FA964FBFFFQ36318564-EFFAFE94-4AAF-47AE-BACC-98C433D25828Q36340098-EA612A7B-A025-4653-8ABD-8C8EC30F8A76Q36604542-0FE54F46-06F7-4665-AA9C-FE61E4809BB1Q36708826-560888D8-A387-4AE9-AE0B-9A9010801AE2Q36835843-AC559AC0-3044-43F4-8863-9969F17AF910Q37050498-040F022B-F8D9-483B-9ADB-079C2FB8152BQ37083640-684CEDD3-B2E5-4E91-B1A2-0F289741000DQ37098218-A4718F42-043D-4B4B-8FE0-F9BD6AF39BE0Q37330178-E3226E62-18D1-48A8-8641-82CBEADFE821Q37677066-94E2910E-63DE-4AF2-8422-35D2B6417BD0Q37860335-764D03F7-E994-4E66-AB45-E292A2945BB7Q37956171-140CD4A1-0695-48F0-A049-4A5E9FD41BDCQ38072056-294B8E1B-E102-49C4-B584-800A237006AEQ38190581-BDFE4A22-3D27-46EC-AFC0-5159C72235E9Q40045544-6984ABF6-6685-4FD7-BC32-A7F860DCB9A7Q40050425-CADC9925-2C26-4FA7-83BA-2BB69A293211Q40073996-BD93174A-5DF4-42FA-B924-8CAD0E347406Q40106774-0B7DC54F-EE9B-403E-B0F7-65169201886DQ40799305-44677CB7-3E9B-4F42-952F-6E44598CA9E8Q40838288-F0E9629C-9457-4F07-A3B6-3136CCF3AF1DQ41204627-7ACF8403-2E3B-43F2-8249-4BEFEDE96BE7
P2860
Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Highly active antiretroviral t ...... improving therapeutic outcome.
@ast
Highly active antiretroviral t ...... improving therapeutic outcome.
@en
type
label
Highly active antiretroviral t ...... improving therapeutic outcome.
@ast
Highly active antiretroviral t ...... improving therapeutic outcome.
@en
prefLabel
Highly active antiretroviral t ...... improving therapeutic outcome.
@ast
Highly active antiretroviral t ...... improving therapeutic outcome.
@en
P2093
P356
P1476
Highly active antiretroviral t ...... improving therapeutic outcome.
@en
P2093
Antonio Mastrolorenzo
Claudiu T Supuran
Giuseppe Barbaro
P304
P356
10.2174/1381612053764869
P577
2005-01-01T00:00:00Z